Navigation Links
Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook
Date:2/28/2011

to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to,   continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... In Follow-up Period -, EXTON, Pa., Jan. ... injections have been completed in the pivotal,Phase III ... Therapy(TM) for the treatment of,nasolabial folds, or wrinkles ... follow-up period of the study., Isolagen also ...
... CLINICAL TRIAL RESULTS PUBLISHED IN THE JOURNAL OF ... 14 BioForm Medical,Inc. (Nasdaq: BFRM ) ... randomized, blinded comparative study of nasolabial fold,treatments reporting ... more effective than Restylane(R), the leading dermal filler,on ...
Cached Medicine Technology:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 2RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 3RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial 4
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... Iridoids and Other ... ... (TNI) today set itself apart from the superfruits of the world yet again as modern ... plant that enhances the overall ability of the body to adapt to stress. Noni assists ...
... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
... ... be a simple matter of getting information about coverage that,s already available ... making concerted efforts to direct the uninsured to coverage, efforts by ordinary ... Charles Smith-Dewey, founder of one of the Web,s most respect health insurance ...
... ... opportunity for educational institutes to discuss their security requirements and compare their current Digital ... , ... (PRWEB) March 4, 2010 -- GlobalSign Inc ( www.globalsign.com ), one of the longest ...
... found that using high-resolution CT-scans to screen for lymphangioleiomyomatosis, or ... who come to the emergency room for the first time ... online ahead of print publication in the American Thoracic Society,s ... Pulmonary LAM is a rare but serious lung ...
... , ... help consumers keep track of their calories by scanning the barcodes on food items has gone ... ... who want to keep track of their daily nutritional intake by scanning the barcodes of items ...
Cached Medicine News:Health News:Tahitian Noni Bioactive Beverages™ Are Adaptogenic 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 2Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 3Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 4Health News:Consumer Health Insurance Site Founder: Health Reform or No Health Reform, Americans Can Help Reduce Rolls of the Uninsured 5Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 2Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 3Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 4Health News:GlobalSign to Demonstrate Online Security Solutions to Educational Institutes at NERCOMP Conference 5Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 2Health News:CT-scan screening for LAM in women with collapsed lung is cost-effective 3Health News:Barcode Joins the Battle of the Bulge in New iPhone App 2
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: